

Liposomal daunorubicin as treatment for Kaposi's sarcoma

Christin E Petre
Dirk P Dittmer

Lineberger Comprehensive
Cancer Center, Center for AIDS
Research (CfAR) and Department
of Microbiology and Immunology,
University of North Carolina, Chapel
Hill NC, USA

Abstract: Anthracycline compounds including daunorubicin are the foundation of many modern chemotherapeutic regimens. However, the side-effects of these compounds can be severe, leading to alopecia, nausea, immune deficiency, and cardiotoxicity. For immunocompromised patients with aggressive Kaposi's sarcoma (KS), these complications often preclude the completion of appropriate chemotherapeutic regimens. This review focuses on the development and efficacy of liposomal daunorubicin (DaunoXome®; DNX) carriers for the treatment of KS. Encouragingly, DNX demonstrated increased in vivo stability and specificity. As a result, KS patients benefit from higher cumulative chemotherapeutic doses without significant cardiotoxicity. Tumor response to DNX treatment surpasses that of non-encapsulated daunorubicin and is similar to that observed with conventional multi-drug therapies such as ABV (doxorubicin, bleomycin, vincristine). Moreover, some reports indicate the patient quality of life during therapy may improve with DNX treatment. Although the development of DNX represents a significant advance in KS therapy, recent data suggest that additional modification of the liposomal carrier to include pegylation or target specific antibodies may further increase daunorubicin efficacy in the future.

Keywords: liposome, Kaposi's sarcoma, anthracycline, KS, doxorubicin

Kaposi's sarcoma

Originally described in the late nineteenth century, Kaposi's sarcoma (KS) has become the most prevalent cancer amongst AIDS patients in the US and worldwide (Engels et al 2006). Until recently the etiological agent of this disease remained elusive. Finally, in 1994, Chang and colleagues isolated viral DNA sequences from KS biopsies, resulting in the identification of the Kaposi's sarcoma-associated herpes virus (KSHV or HHV-8) (Chang et al 1994). KSHV is maintained latently in all KS tumors and thus is believed to be the causative agent of the disease (Chang et al 1994; Cesarman et al 1995; Soulier et al 1995). Several forms of KS are currently recognized, including classic, endemic, iatrogenic (transplant associated), and AIDS-associated (Tappero et al 1993). Among the few cases of KS reported in the US prior to the onset of the AIDS epidemic, most were iatrogenic or found in elderly men of Mediterranean descent (classic). In contrast, endemic KS has always been prevalent in Africa, and today has become the most frequently observed pediatric cancer in this population following the rise of the HIV epidemic. AIDS-associated KS first became prevalent worldwide during the 1980s into the early 1990s in men who have sex with men. It has declined following the implementation of highly active anti-retroviral therapy (HAART), as have many other of the original AIDS-defining conditions (Eltom et al 2002; Casper 2006; Engels et al 2006). Unfortunately, HAART has had no effect on the incidence of classic, iatrogenic, or endemic KS nor is HAART available to populations who presently experience the highest prevalence of HIV, such as in Africa. More alarming, cases of AIDS-associated KS are now emerging in patients receiving HAART and who maintain adequate immune function (Koon et al 2005; Boshoff 2006; Casper 2006).

Correspondence: Dirk P Dittmer
University of North Carolina at Chapel
Hill, CB# 7290, 727 Mary Ellen Jones Bldg,
Chapel Hill, NC 27599-7290, USA
Tel +1 919 966 7960 (office)
+1 919 966 7962 (lab)
Fax +1 919 962 8103
Email ddittmer@med.unc.edu

As the number of HIV-positive individuals continues to grow worldwide, KS is re-emerging as a more aggressive and prominent tumor type.

The changing nature of KS is reflected in 5-year survival data reported by the NCI Surveillance Epidemiology and End Results (SEER) program (Figure 1). As mentioned above, most KS cases in the US prior to 1980 were dermal, minimally aggressive, and often associated with elderly white men. For these patients, KS was rarely life threatening and over 80% survived more than 5 years. During the height of the US HIV epidemic and prior to the onset of HAART, a more aggressive KS tumor emerged. Dramatically, 5-year survival rates in KS patients plummeted from 1985 to 1989. Following the implementation of HAART and the development of KS-specific treatment regimens (interferon alpha, taxol, and combination chemotherapy) the US witnessed a substantial decrease in patient mortality. Yet, even today, less than 50% of all KS patients in the US, ie, with ready access to HAART, reach the 5-year survival mark. The outlook is even worse for the growing number of African American KS patients. Clearly, our ability to treat KS patients both now and in the future is dependent upon the development of novel and efficacious treatment

regimens against KS. Restoring immune sufficiency alone does not suffice.

Current KS therapy ranges from watchful waiting to aggressive chemotherapy and is largely dependent upon the lesion location, size, and extent. Localized, non-progressive disease is easily treated through cryotherapy, argon laser excision, local chemotherapeutic injection, or localized radiation. Response rates vary with each of these treatment regimens, but have been reported to reach up to 90% (Krown et al 2004). For AIDS-associated and iatrogenic KS, immune reconstitution is sometimes sufficient to trigger tumor remission. HAART alone caused KS remission in 48%–86% of HIV positive KS patients (Lebbe et al 1998; Dupin et al 1999; Dupont et al 2000; Cattelan et al 2001; Murdaca et al 2002; Paparizos et al 2002; Wilkinson et al 2002). Similarly, iatrogenic KS can be controlled by limiting the dosage, or switching the type of immunosuppressive therapy employed. However, recent evidence suggests that immune reconstitution is not the sole factor leading to KS regression. Protease inhibitors associated with modern day HAART may also possess anti-KS activities (Monini et al 2004). Moreover, our recent findings along with those reported by Stallone et al suggest that some immunosuppressive drugs like rapamycin




Figure 1 KS survival rates during the rise of the HIV/AIDS pandemic. Data bars represent the percentage of individuals reported by the NCI Surveillance Epidemiology and End Results (SEER) program to have survived 5 years post-diagnosis.

may specifically target KSHV-infected tumors (Stallone et al 2005; Sin et al 2006).

Visceral organ involvement represents the most severe manifestation of KS, and lesions have been reported in the lungs, gastrointestinal tract, lymph nodes, heart, bone, and spleen of affected individuals (Krown et al 2004). For such disseminated or rapidly progressing forms of KS more aggressive therapies must be employed. Classically, a combination of multiple chemotherapeutics has been utilized (eg, CHOP – cyclophosphamide, hydroxydoxorubicin, vincristine/Oncovin®, prednisone; ABV – doxorubicin, bleomycin, vincristine; and BV – bleomycin, vincristine). Alternatively, interferon alpha, paclitaxol, and etoposide effectively treat disseminated KS and are FDA-approved for this purpose (Real et al 1986; Lane et al 1988; Krown et al 1993; Welles et al 1998; Gill et al 1999; Evans et al 2002). However, the side-effects of chemotherapeutic drug regimens limit their efficacy, especially in immunocompromised KS patients. Anthracycline drugs in particular (eg, doxorubicin, epirubicin, idarubicin, daunorubicin) present a secondary challenge to patient health due to their known cardiotoxic side-effects (Elliott 2006). In order to combat these issues, targeted drug delivery systems have been developed for several anthracycline compounds. This review focuses on the pharmaceutical advancements that have aimed to improve both the efficacy and tolerability of daunorubicin in KS treatment.

Daunorubicin

Originally isolated from *Streptomyces peucetius varcaesitue*, daunorubicin (DNR) has become a mainstay in modern chemotherapy (Dimarco et al 1964; Behal 2000). DNR belongs to the anthracycline family of compounds, which hold intrinsic antibiotic and anti-tumor activities. Structurally, anthracyclines contain a daunosamine sugar linked to naphthacene via an O-glycosidic bond (see Figure 2) (Robert 1998). Differences in the naphthacene derivative differentiate




Figure 2 Structure of daunorubicin.

DNR from other anthracyclines and change the pharmacokinetic properties of the compound (Robert 1998). DNR is believed to function through multiple mechanisms to mediate DNA damage (Sinha and Politi 1990). Intercalation of the daunosamine residue into the minor groove of cellular DNA leads to local DNA unwinding (Crooke et al 1978; Chaires et al 1982; Chaires 1990; Nabiev et al 1991; Belloc et al 1992). It is hypothesized that these DNA–DNR complexes serve as a blockade for cellular replication. Alternatively, the activity of topoisomerase II, an enzyme that relieves torsional stress during DNA synthesis, is also significantly inhibited by DNR (Tewey et al 1984; Froelich-Ammon and Osheroff 1995). Anthracyclines stabilize interaction between topoisomerase II and cleaved DNA, preventing the enzyme from fully resolving DNA breaks (Tewey et al 1984). Finally, cellular metabolism of DNR leads to the formation of free radical species capable of inducing DNA damage (Handa and Sato 1975; Doroshow and Davies 1986; Sinha 1989). Thus, through the non-specific targeting of DNA replication, DNR targets all cells with a high proliferation index. Cell cycle progression prior to complete repair of these DNR-induced DNA lesions can result in chromosomal instability or trigger cell death. Since normal cells of the body must also proliferate to maintain homeostasis, significant side-effects including alopecia, nausea, and vomiting are often observed in patients receiving DNR therapy. In order to alleviate some of these adverse side-effects, a liposomal DNR derivative was developed.

Liposomal formulation

Phospholipid spheres were originally discovered and termed liposomes in the 1960s (Bangham et al 1965; Sessa and Weissmann 1968). Now tailored for use in drug formulations, liposomes can be classified based on lamellarity, size, makeup, and biological distribution (Hofheinz et al 2005; Netageri 1993). Unilamellar liposomes, composed of a single lipid bilayer, are frequently used to encapsulate water soluble drugs (Hofheinz et al 2005), and can be further classified based on size. Small unilamellar liposomes (SUV) are typically 25–100 nm in diameter, whereas large unilamellar liposomes (LUV) are significantly bigger (100–400 nm) (Netageri 1993). Multilamellar liposomes (MLV) range from 100 nm to over 1 µm in size and contain several concentric lipid bilayers (Netageri 1993). In contrast to SUV and LUV, MLV are used frequently to package lipid soluble drugs (Hofheinz et al 2005).

The liposomal structure is hypothesized to stabilize encapsulated drugs in vivo. Liposomes flowing in the blood

fail to extravasate intact blood vessels, accumulating instead in areas of discontinuous capillaries, such as tumor tissue (Jain 1987; Dvorak et al 1988; Huang et al 1992; Hobbs et al 1998). In this manner, therapeutic toxicity should be reduced while increasing tumor uptake. Moreover, since KS is a highly vascularized tumor characterized by capillary leakage, this property of liposomal drug formulations may increase therapeutic efficacy. Unfortunately, all liposomes also naturally target the reticuloendothelial system (RES) of the body, which includes the liver, spleen, and bone marrow (Patel and Russell 1988; Huang et al 1992). While circulating in the blood, liposomes bind plasma proteins, immunoglobulins, and complement leading to RES-uptake via opsonization (Chonn et al 1992; Cullis et al 1998). Extremely large liposomes, like the giant MLVs ($>1\ \mu\text{m}$), are also trapped and concentrated within the small, alveolar capillaries of the lungs (Hwang 1987). Certainly, it could be envisioned that liposomal uptake by the RES would have significant advantages for the delivery of potential immunomodulatory therapeutics. However, for most anti-cancer agents this property is undesirable.

Several RES-targeting liposomal drug formulations have been developed using a wide variety of strategies. These drugs have advantages over classic therapies, reducing a number of the toxicities previously associated with anthracycline administration (Roerdink 1987). Some of the first forms of liposomal doxorubicin (LD) employed acidic lipids to draw in the weakly basic drug (Allen 2004). Other approaches establish a liposomal pH gradient, pulling the drug towards the core of each lipid sphere (Mayer et al 1986; Li et al 1998). Such technology is utilized in the formulation of therapeutics currently on the market including Myocet® (LD; Medeus Pharma) and Onco TCS® (liposomal vincristine; INEX Pharmaceuticals) (Embree et al 1998; Gelmon et al 1999; Allen and Martin 2004). Finally, RES-targeting liposomes can be formulated to contain lipid-soluble drugs within the liposomal membrane. Notably, LEP ETU®, a form of liposomal paclitaxel manufactured by NeoPhar, is manufactured using this technology (Treat et al 2001; Allen and Martin 2004).

As scientists learn more about the biological properties of liposomes, it has become feasible to develop RES-avoiding drug formulations. Clearly, a reduction in RES uptake provides many pharmacokinetic and biological benefits to any chemotherapeutic. Toxicity, specificity, and plasma half-life are increased by RES avoidance. Several methodologies have been developed that limit RES exposure. Most simply, patients may be subjected to RES saturation with empty

liposomes prior to therapeutic administration. This approach limits RES uptake but may have significant, long-term effects on RES function (Abra et al 1980; Allen 1988). Modeling the RES avoidance by erythrocytes, scientists have incorporated polyethylene glycol (PEG) in the lipid bilayer of some liposomes. This “stealth” technology greatly extends the drug half-life through a reduction in RES uptake (reviewed in Allen and Martin 2004). Doxil, a PEG-coated form of liposomal doxorubicin (PLD), is the first FDA-approved KS therapy to employ STEALTH® technology (see Figure 3). This approach as well as other RES-avoiding technologies including DaunoXome® (liposomal daunorubicin; DNX) have been highly successful and represent a wave of newly formulated liposomal therapeutics.

Already new technology is being developed to further the targeting specificity of liposomal carriers. Cationic liposomes show high affinity for tumor neovasculature and may demonstrate increased efficacy for highly angiogenic tumor types (Thurston et al 1998). In addition, scientists are working to incorporate specific receptors, tumor ligands, and antibodies in future liposomal drug formulations. These modifications should lead to the development of tumor-specific therapies with limited side-effects and maximum efficacy.

Pharmacology and kinetics

DaunoXome®, a liposomal formulation of DNR (DNX), was first licensed in the United Kingdom in 1995 and later approved by the FDA. This liposomal formulation, manufactured by Gilead Pharmaceuticals Inc. (San Dimas, CA), is uniquely formulated to be RES-avoiding. Specifically, DNX is the first liposomal derivative of its kind to be made solely of lipids (Allen and Martin 2004). Composed of three major components: distearoylphosphatidylcholine (DPC), cholesterol, and DNR, DNX liposomes are small (45 nm) and neutrally charged (Gilead Sciences 2000; Allen and Martin 2004). Formulation of DNR into a citrate salt assists in drug encapsulation. Due to the small size and relative neutrality of DNX particles, RES uptake is minimized, leading to prolonged drug circulation (Forssen et al 1992). However, in murine model systems, RES absorption of DNX remains 60%–110% higher than that observed during conventional DNR therapy (Gilead Sciences 2000).

Evidence that the pharmacokinetics of DNX would differ greatly from those observed with conventional DNR first came from murine xenograft models. In preclinical trials, mice with lymphosarcoma (P-1798)-derived tumors or mammary adenocarcinoma (MA16C)-derived tumors were treated and monitored for DNX pharmacokinetics (Forssen et al 1992). Plasma DNR




Figure 3 Structure of a STEALTH® liposome. A soluble drug component such as daunorubicin is contained within a single lipid bilayer. Addition of polyethylene glycol polymers to the liposomal surface (STEALTH technology) leads to decreased RES uptake and increased drug stability (adapted from Allen and Martin 2004).

levels were consistently higher in DNX-treated mice compared with conventional DNR. Clearance of free DNR occurred rapidly (44.9 mL/h) compared with the liposomal formulation (0.195 mL/h). Although the rate of tumor drug accumulation was much higher in mice treated with conventional therapy ($k_a = 2.64/h$) than those receiving DNX ($k_a = 0.265/h$), area under the curve (AUC) values increased 10 times with the liposomal formulation. Differences in pulmonary and cardiac uptake were negligible, suggesting that toxicity to these organs would be limited. As a result, tumor progression as well as mortality significantly decreased in DNX-treated mice. The authors attribute the plasma stability of liposomal DNR to the incorporation of high phase transition temperature of DPC and the addition of cholesterol to the encapsulating lipid bilayer. This stability is required to maintain elevated DNX serum levels long enough to allow for effective tumor uptake. Once entrapped in the fenestrated capillaries of the tumor, DNR becomes bioavailable and functions to effectively limit tumor growth. These tumor-specific targeting properties made liposomal DNR attractive for future clinical studies.

Following the success of DNX in animal models, several clinical trials examined the pharmacokinetic properties of

this novel drug formulation in patients. At the time, KS was emerging as a serious threat to the growing number of AIDS patients worldwide. Even though animal models of KS did not become available until recently (An et al 2006) and, therefore, DNX was never tested preclinically in a bona fide KS-model, there was a strong push to get FDA approval. For this reason, the properties of DNX in KS patients were examined by several groups. The first study, reported in 1995, examined the pharmacokinetics, response, and toxicity of increasing DNX dosages (Gill et al 1995). From these data, a dosage between 40 and 60 mg/m² was shown to be most efficacious. As a result the recommended DNX dosage was set to 40 mg/m² every 2 weeks, a standard which still holds true today (Gilead Sciences 2000). At these levels, reports of mean plasma AUC range from 114.91 to 120.1 µg h⁻¹ mL⁻¹ (Gill et al 1995; Fumagalli et al 2000). These data represent an 11- to 12-fold increase over conventional DNR and reflect the stability of the liposomal carrier as previously described in murine model systems (Forssen et al 1992; Gill et al 1995). Likewise, clearance is significantly reduced in DNX treated patients when compared with those treated with conventional drug (10.5 mL/min vs 233 mL/min, respectively)

(Alberts et al 1971; Gill et al 1995; Fumagalli et al 2000). These two properties combine to stabilize serum DNX, resulting in a half life between 4 and 5.6 h ($t_{1/2}$ DNR \approx 0.77 h) (Gill et al 1995; Fumagalli et al 2000). Peak plasma levels range from 14.8 to 22 μ g/mL and far surpass those previously observed with conventional DNR treatment (Alberts et al 1971; Gill et al 1995; Fumagalli et al 2000). These results suggest that the increased stability of liposomal DNR may provide a mechanism by which high cumulative doses may be administered to patients without serious side-effects. As a result, the efficacy and tolerability of DNX was anticipated to surpass all previous DNR formulations.

Efficacy in KS treatment

Evaluation of the efficacy of an individual KS treatment modality is largely dependent upon the implementation of standard of staging criteria. Unfortunately, many of the initial DNX studies were conducted before the implementation of the Aids Clinical Trials Groups (ACTG) response criteria. In 1989 Krown et al proposed this standard method of staging to assess KS response to clinical trial regimens (Krown et al 1989). The scope of KS involvement is often difficult to assess and may be confounded by other underlying conditions, especially in the context of HIV-AIDS. Determining the extent of visceral disease can be difficult and in the past has been scored mainly upon the severity of patient symptoms. The ACTG criteria have defined a distinct and stringent set of characteristics to classify therapeutic response (see Table 1). Specifically, the appearance of any

new lesion or the progression of any KS-related symptom excludes patients from achieving either complete or partial response even if as a whole, the individual experiences a therapeutic benefit (Krown et al 1989). As a result of these stricter criteria, studies conducted using ACTG guidelines show a significant decrease in patient response rates compared with studies conducted using non-standard evaluation criteria (Gill et al 1996). Even with the implementation of the ACTG guidelines, many factors may influence the reported success rate of individual trials, including patient CD4 count, treatment history, and concurrent drug administration (Presant et al 1993; Gill et al 1995; Fumagalli et al 2000; Rosenthal et al 2002).

The first DNX trials focused on the safety and potential therapeutic benefits of liposomal DNR in the treatment of AIDS-associated KS. Three separate phase I/II clinical trials monitored the response of over 115 HIV-positive KS patients (Presant et al 1993; Gill et al 1995; Tulpule et al 1998). The severity of KS varied greatly among the study participants, but most patients were classified as having highly aggressive disease. Previous treatment with chemotherapy was not used as an exclusion parameter. Once drug safety was established at lower doses (Presant et al 1993; Gill et al 1995), study participants were treated every 2 weeks with 40–60 mg/m² i.v. DNX. Overall response rates (representing those with complete or partial tumor regression), as determined by differential standards, varied from 55% to 60% (Presant et al 1993; Gill et al 1995; Tulpule et al 1998). Response

Table 1 Aids Clinical Trials Groups response criteria for AIDS-related Kaposi's sarcoma

Response classification	Tumor-associated edema	Lesions	Visceral disease	Required response duration
Complete response (CR)	None	None ¹	None ²	\geq 4 weeks
Partial response (PR)	No increase or new appearance	1. \geq 50% decrease in # or size of previous lesions ³ 2. No new lesions or areas of involvement 3. No increase \geq 25% in the product of bidirectional indicator lesion diameter ⁴	No increase or new sites of involvement	\geq 4 weeks
Stable disease (SD)	Any non-PR response	Any non-PR response	Any non-PR response	Not specified
Progression	New edema or effusion	1. \geq 25% increase in the size, #, or sites of disease involvement 2. \geq 25% change in lesion appearance from macular to plaque-like/nodular	Any increase	Not specified

Notes: As described in Krown et al 1989 ¹If brown/tan macular lesions persist, at least one representative must be biopsied and shown to be free of malignancy;

²Verification by restaging is required, otherwise only a clinical CR may be declared; ³Defined as a \geq 50% decrease in the sums of the products of the largest perpendicular diameters of bidimensionally measurable marker lesions and/or complete flattening \geq 50% of previously nodular lesions; ⁴In patients with predominantly nodular lesions, flattening of \geq 75% is considered PR.

of pulmonary KS alone was even higher, wherein 75% of study participants experienced complete or partial response according to ACTG standards (Tulpule et al 1998). These results, which showed disease regression with few side-effects, provided a rationale to pursue DNX as a novel KS therapy.

The ABV regimen is a classic first-line defense against aggressive or disseminated KS. In clinical trials, the response rates to such combination drug therapy are reported to range from 33% to 88% (Krown et al 2004). To compare the efficacy of DNX with conventional ABV, Gill and colleagues performed a prospective study of 227 HIV-positive KS patients (Gill et al 1996). Study participants were randomized to two treatment arms, 40 mg/m² DNX or ABV (10 mg/m² doxorubicin, 15U bleomycin, 1 mg vincristine) every 2 weeks. Only patients with advanced KS and no prior systemic chemotherapy were admitted into the trial. All localized treatments had to be discontinued at least 14 days before study enrollment. Surprisingly, ACTG response rates between the two arms of the trial were comparable (25% and 27.9% for DNX and ABV, respectively) with most patients achieving stable disease (58%–62%). No significant difference was observed in time to progression or survival. Complete remission was documented in both DNX- and ABV-treated study participants. Together, these data show that DNX efficacy is not distinguishable from that of conventional, multi-drug ABV therapy.

AIDS-associated KS represents a unique challenge wherein the decision to implement HAART in addition to chemotherapeutic regimens needs to be considered. In fact, in AIDS-associated lymphoma HAART can be delayed until all chemotherapy cycles have been concluded. Even though concomitant administration of HAART and combination-chemotherapy is considered safe and effective (Ratner et al 2001), the use of AZT with chemotherapy was previously contraindicated (Lim and Levine 2005). Importantly, withholding HAART during chemotherapy is safe, allows for the administration of higher dose therapy, and does not modulate AIDS progression (Little et al 2003). Whether these lymphoma-specific recommendations also applied to DNX administration in KS was previously unknown.

Protease inhibitors are known to block the activity of cytochrome p450_{III A4} (CYP3A4), which metabolizes anthracycline drugs (von Moltke et al 1998). Due to this property, the efficacy of anthracycline therapy in combination with HAART was formerly questioned. The emergence of HAART-resistant HIV strains has since led to the desire to maintain anti-retroviral treatment during the course of

anthracycline administration. To determine the ramifications of proteasome inhibitor co-administration, Fumagalli and colleagues examined DNX pharmacokinetics in the presence or absence of HAART (Fumagalli et al 2000). Eighteen individuals with rapidly progressing visceral, pulmonary, gastrointestinal, or mucocutaneous KS were enrolled in the study. Of the participants, 39% had undergone prior chemotherapy. Although the pharmacokinetic properties of DNX (delivered at 40 mg/m²) were unaltered by concomitant administration of any nucleoside reverse transcriptase inhibitor (NRTI)-protease inhibitor cocktail, prior anthracycline therapy significantly increased both peak DNX concentration and plasma AUC. These data suggest that prior chemotherapeutic treatments may influence DNX efficacy. Regardless, most study participants (82.3%) achieved either complete or partial response. Together, these findings suggest that HAART does not influence DNX efficacy; however, the effect of anthracycline therapy on the activity of protease inhibitors remains to be addressed.

Although these trials demonstrate that DNX is efficacious in the treatment of AIDS-associated KS, several patient attributes clearly effect therapeutic outcome. Recent reports suggest that prior administration of anthracycline therapy modulates both drug pharmacokinetics and KS response (Presant et al 1993; Gill et al 1995; Fumagalli et al 2000). Gill and colleagues examined this observation in detail, finding that prior chemotherapy as a whole does not influence patient response (Gill et al 1995). However, in study participants previously treated with anthracycline therapies, a significant difference in therapeutic efficacy was observed ($p = 0.004$) (Gill et al 1995). Whether these observations can be attributed to therapeutic resistance or differences in DNX kinetics is unclear; however, it is clear that patient treatment history may influence the choice to begin liposomal DNR treatment. CD4 count also appears to affect DNX efficacy. Patients with a CD4 count below 100 have a significantly lower probability of responding to DNX therapy ($p = 0.004$), suggesting that control of HIV is essential to successful KS treatment (Gill et al 1995). Clearly, additional studies are required to assess the influence of these predisposing factors on DNX efficacy.

Tolerability and toxicity

Production of liposomal anthracycline compounds was pioneered with the goal of producing therapeutics with higher specificity and potency while limiting patient side-effects. A major concern of any anthracycline treatment modality is cardiotoxicity. Both congestive heart failure

and cardiomyopathy have been reported to occur in a dose-dependent manner upon DNR treatment (Lefrak et al 1973; Von Hoff et al 1979). To prevent the significant complications associated with anthracycline cardiotoxicity, patient left ventricular ejection fraction (LVEF) is closely monitored. In general, individuals demonstrating an LVEF of less than 45% were excluded from all initial DNX studies (Gill et al 1996; Tulpule et al 1998). Direct comparison of cardiac function in patients treated with DNX vs ABV revealed no significant difference in LVEF during treatment (Gill et al 1996). Only one report to date has documented any LVEF decline following DNX administration. Moreover, upon further review of the effected individual's case history, prior anterior myocardial infarct was noted (Gill et al 1996). Thus, although cumulative doses in many trials reached levels of over 600 mg/m² (Gill et al 1995, 1996; Tulpule et al 1998; Rosenthal et al 2002; Young et al 2004), DNX fails to induce significant cardiotoxicity.

The most prominent DNX side-effect reported in all clinical trials was severe leukopenia, which was observed in 11%–17% of treatment cycles (Gill et al 1995; Fumagalli et al 2000). Most notably, in one trial, 85% of patients receiving a dose of 60 mg/m² DNX every 2 weeks experienced grade 3/4 neutropenia (Tulpule et al 1998). Moreover, the increased incidence of leukopenia in DNX- vs ABV-treated individuals was statistically significant ($p = 0.021$) (Gill 1996). To combat this adverse effect, hemopoietic growth factors (eg, granulocyte colony-stimulating factor, G-CSF) were administered following 15%–29% of DNX treatment cycles and appeared to be effective in limiting further leukopenia (Fugamalli 2000; Rosenthal 2002). Other severe DNX-specific side-effects were not observed.

DNX patients develop alopecia and neuropathy less frequently than those treated with other cytostatic regimens ($p < 0.0001$) (Gill et al 1996). No other significant differences were found between patients treated with liposomal DNR vs conventional chemotherapy (Gill et al 1996). Specifically, nausea, fever, and fatigue were similar among treatment regimens (Gill et al 1996). In several reports, fever, flushing, and back pain were reported within the first 5 minutes of DNX administration. However, patients were typically able to resume therapy at a slower infusion rate without significant distress (Gill et al 1996). Table 2 summarizes the complications observed in DNX trials for KS. Overall, DNX treatment appears to limit some of the adverse side-effects of conventional chemotherapy (Presant et al 1993; Gill et al 1995, 1996; Fumagalli et al 2000; Rosenthal et al 2002).

Table 2 Complications observed in clinical trials of liposomal daunorubicin

Report	Overall response	Cardiotoxicity	Neuropathy	Alopecia	Neutropenia	Leukopenia	Fatigue	Nausea	Opportunistic infection
Gill et al 1996	29%	1/116 showed LVEF decline ^a Other cardiac events: 6.0%	Grade 1/2: 12% Grade 3/4: 1%	Grade 1/2: 8% Grade 3/4: 0%	Grade 1/2: 67% Grade 3/4: 51%	Grade 1/2: 91% Grade 3/4: 38%	Grade 1/2: 43% Grade 3/4: 6%	Grade 1/2: 51% Grade 3/4: 3%	36%
Gill et al 1995 Fumagalli et al 2000	55% 82%	None observed No reduction of LVEF to below 50%	0% NR	Grade 1: 5% NR	17% of cycles NR	NR 11.1%–13.3% of cycles	Grade 1/2: 59% NR	Grade 1/2: 46% NR	NR 0%
Rosenthal et al 2002	38%	No worsening or appearance of cardiac events	NR	NR	29% of cycles required treatment	NR	NR	NR	8%
Presant et al 1993	71%	Observed only in patients with pre-existing heart conditions	NR	Grade 1: 16% Grade 2–4: 0%	NR	NR	NR	Grade 1/2: 20% Grade 3/4: 0%	NR
Tulpule et al 1998	32%	No decline in LVEF observed	NR	11%	Grade 3/4: 85%	NR	54%	53%	NR

^aPatient case history showed previous myocardial infarct

Abbreviations: LVEF, left ventricular ejection fraction, NR, not reported.

Several clinical trials have monitored patient quality of life (QOL) during DNX treatment. During one study, both physical and emotional performance increased over 70% during DNX treatment (Presant et al 1993). A second study comparing DNX with ABV showed that patients within the DNX study arm maintained QOL whereas QOL gradually declined with ABV treatment (Gill et al 1996). Although the significance of these data is unclear, the trend suggests that DNX treatment may be more tolerable than conventional chemotherapy, especially during long-term treatment regimens.

Pharmacoeconomics

When considering any new medical intervention, the costs of therapy must be weighed against the potential benefits. For aggressive KS, several treatment options are now available, including conventional chemotherapies (eg, ABV, BV, CHOP), interferon alpha, vinca alkaloids, taxanes, and liposomal anthracyclines (reviewed in Krown et al 2004). In general, liposomal drug formulations are more costly than conventional chemotherapy and are at present unaffordable in the areas of greatest need such as in Africa. However, the potential for these drugs to significantly reduce the adverse effects of anthracyclines make them attractive. To date, no direct comparison of PLD (Doxil®) with DNX has been conducted for KS, yet an indirect comparison can be made assuming that the patient cohorts and response criteria are essentially the equal. In 2008, Bennett and colleagues used data from the DNX vs ABV (Gill et al 1996) and PLD vs BV (Stewart et al 1998) trials to estimate the cost-effectiveness of each liposomal therapy. While DNX is clearly more affordable upfront (US\$538/cycle vs US\$1212/cycle with PLD) (Bennett et al 1998), the number of cycles required for response as well as the costs associated with G-SCF administration must be included in order to properly compare the two therapies. During DNX treatment a higher number of patients required granulocyte-colony stimulating factor (G-SCF) therapy, in addition an average of 8.6 cycles of DNX vs 4.8 cycles of PLD were necessary for patient response (Gill et al 1996; Bennett et al 1998; Stewart et al 1998). Taking these factors into account, the cost of DNX treatment was still ~US\$445 less than PLD (Bennett and Calhoun 2004).

In both studies, patient outcome was monitored by ATCG standards at the conclusion of the trial. Response rates for PLD vs DNX were 59% and 25%, respectively (Gill et al 1996; Stewart et al 1998). Due to this disparity among treatment regimens, the cost-effectiveness ratio (the cost associated with achieving one response) was twice as high for DNX (US\$26,483) as for PLD (US\$11,976) (Bennett et al 1998).

In a study of Swedish patients, similar results were obtained, demonstrating that PLD is more cost effective than DNX for the treatment of KS (Hjortsberg et al 1999).

Comments and conclusions

Treatment of aggressive KS has long relied upon the activity of combination chemotherapy. Although largely successful, these treatments carry many serious side-effects. The arrival of the liposomal anthracycline formulations provides patients new therapeutic options to combat KS. Herein, we discussed the pharmacokinetics, efficacy, and tolerability of DNX in AIDS-associated KS patients. Although response rates varied between trials, DNX proved superior to conventional DNR treatment and comparable to ABV (Gill et al 1996). The liposomal formulation stabilizes DNR, preventing rapid clearance and allowing more time for the drug to accumulate in KS lesions (Forssen et al 1992; Gill et al 1995). Notably, as observed with other liposomal anthracycline formulations, cardiotoxicity is limited even in the presence of high cumulative DNR doses (≥ 500 mg/m²) (Gill et al 1995; Gill et al 1996; Tulpule et al 1998). Although DNX costs less per cycle than other liposomal anthracyclines on the market, indirect comparison suggests that PLD is actually more cost-effective due to an increased response rate (Bennett and Calhoun 2004). As both prior chemotherapeutic treatment as well as CD4 count have been reported to influence patient response to DNX (Gill et al 1995), it may be important to determine patient response in the context of naïve, CD4 high (>100/ μ L) individuals. In this setting, DNX may show significant promise.

Currently Doxil (PLD) represents the major competitor to DNX therapy. In general, patient response to Doxil requires fewer treatment cycles and thus is more cost effective (Gill et al 1996; Stewart et al 1998; Bennett and Calhoun 2004). It is clear that the pegylated, STEALTH®, formulation of Doxil further limits RES uptake, resulting in longer periods of drug circulation in vivo (Allen and Martin 2004). Whether similar formulations of DNR would prove more efficacious in the treatment of KS is unclear since anthracyclines display virtually identical mechanistic properties. Importantly, each new advance in liposomal technology has increased drug efficacy, specificity and tolerability, leading to better therapeutic options for patients with KS.

Strikingly, the efficacy of DNX has been predominantly evaluated in the context of HIV-positive males. Although there is an urgency to develop more effective drugs for AIDS-associated KS, little is known about the effects of DNX on HIV-negative patients. Previous reports have observed no difference in the response rates of endemic vs epidemic KS

to therapy (Stein et al 1994; Kigula-Mugambe and Kavuma 2005). However, patient HIV status is sure to influence DNX efficacy as CD4 count significantly influences therapeutic outcome (Gill et al 1995). Clinical trials have thus far failed to address DNX efficacy in females. In fact, less than 1% of DaunoXome study participants were female (Presant et al 1993; Gill et al 1995, 1996; Tulpule et al 1998; Fumagalli et al 2000). These data reflect the predominantly male HIV population at the outset of the AIDS epidemic in the US. To date, however, females account for almost half of the HIV-positive population world-wide (Quinn and Overbaugh 2005; UNAIDS 2006). Over 25% of patients diagnosed with HIV in 2004 were women and this number continues to grow (CDC 2006). In areas where KS is endemic and spread by non-sexual as well as sexual routes, KS is found in women and female children almost as frequently as in men. As women often display differential drug metabolics, it is essential that additional studies be conducted in female KS patients in order to clearly understand and assess DNX efficacy.

Finally, use of universal response criteria, such as those provided by the ATCG or recently proposed (CIT-NEJM), should greatly improve our ability to assess therapeutic efficacy. Proper assessment of visceral disease may require the advent of new technologies to improve KS detection and characterization. Additionally, future development of DaunoXome to decrease RES-uptake may be needed in order to compete with the pegylated anthracycline formulations currently on the market. Still, DNX clearly represents a significant advance in KS chemotherapy, providing multiple benefits over conventional, ABV-like therapies and potentially improving patient QOL.

References

- Abra RM, Bosworth ME, Hunt CA. 1980. Liposome disposition in vivo: effects of pre-dosing with liposomes. *Res Commun Chem Pathol Pharmacol*, 29:349–360.
- Alberts DS, Bachur NR, Holtzman JL. 1971. The pharmacokinetics of daunomycin in man. *Clin Pharmacol Ther*, 12:96–104.
- Allen TM. 1988. Toxicity of drug carriers to the mononuclear phagocyte system. *Adv Drug Deliv Rev*, 2:55–67.
- Allen TM, Martin FJ. 2004. Advantages of liposomal delivery systems for anthracyclines. *Semin Oncol*, 31:5–15.
- An FQ, Folarin HM, Compitello N, et al. 2006. Long-term-infected telomerase-immortalized endothelial cells: a model for Kaposi's sarcoma-associated herpesvirus latency in vitro and in vivo. *J Virol*, 80:4833–46.
- Bangham AD, Standish MM, Watkins JC. 1965. Diffusion of univalent ions across the lamellae of swollen phospholipids. *J Mol Biol*, 13:238–52.
- Behal V. 2000. Bioactive products from Streptomyces. *Adv Appl Microbiol*, 47:113–56.
- Belloc F, Lacombe F, Dumain P, et al. 1992. Intercalation of anthracyclines into living cell DNA analyzed by flow cytometry. *Cytometry*, 13:880–5.
- Bennett CL, Calhoun EA. 2004. Pharmacoeconomics of liposomal anthracycline therapy. *Semin Oncol*, 31:191–5.
- Bennett CL, Golub RM, Stinson TJ, et al. 1998. Cost-effectiveness analysis comparing liposomal anthracyclines in the treatment of AIDS-related Kaposi's sarcoma. *J Acquir Immune Defic Syndr Hum Retrovirol*, 18:460–5.
- Boshoff C, Weiss RA (eds). 2006. Kaposi Sarcoma Herpesvirus: New Perspectives. New York: Springer.
- Casper C. 2006. Defining a role for antiviral drugs in the treatment of persons with HHV-8 infection. *Herpes*, 13:42–7.
- Casper C, Krown SE. 2006. Presented at: 10th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies. Bethesda, MA, USA.
- Cattelan AM, Calabro ML, Gasperini P, et al. 2001. Acquired immunodeficiency syndrome-related Kaposi's sarcoma regression after highly active antiretroviral therapy: biologic correlates of clinical outcome. *J Natl Cancer Inst Monogr*, 28:44–49.
- Centers for Disease Control and Prevention (CDC). 2006. HIV/AIDS Surveillance Findings [online]. Accessed 16 October 2006. URL: <http://www.cdc.gov/hiv/topics/women/surveillance.htm>
- Cesarman E, Chang Y, Moore PS, et al. 1995. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. *N Engl J Med*, 332:1186–91.
- Chaires JB. 1990. Biophysical chemistry of the daunomycin-DNA interaction. *Biophys Chem*, 35:191–202.
- Chaires JB, Dattagupta N, Crothers DM. 1982. Studies on interaction of anthracycline antibiotics and deoxyribonucleic acid: equilibrium binding studies on interaction of daunomycin with deoxyribonucleic acid. *Biochemistry*, 21:3933–40.
- Chang Y, Cesarman E, Pessin MS, et al. 1994. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. *Science*, 266:1865–9.
- Chonn A, Semple SC, Cullis PR. 1992. Association of blood proteins with large unilamellar liposomes in vivo. Relation to circulation lifetimes. *J Biol Chem*, 267:18759–65.
- Crooke ST, Duvernay VH, Galvan L, et al. 1978. Structure-activity relationships of anthracyclines relative to effects on macromolecular syntheses. *Mol Pharmacol*, 14:290–8.
- Cullis PR, Chonn A, Semple SC. 1998. Interactions of liposomes and lipid-based carrier systems with blood proteins: Relation to clearance behaviour in vivo. *Adv Drug Deliv Rev*, 32:3–17.
- Dimarco A, Gaetani M, Dorigotti L, et al. 1964. Daunomycin: a new antibiotic with antitumor activity. *Cancer Chemother Rep*, 38:31–8.
- Doroshov JH, Davies KJ. 1986. Redox cycling of anthracyclines by cardiac mitochondria. II. Formation of superoxide anion, hydrogen peroxide, and hydroxyl radical. *J Biol Chem* 261:3068–74.
- Dupin N, Rubin De Cervens V, Gorin I, et al. 1999. The influence of highly active antiretroviral therapy on AIDS-associated Kaposi's sarcoma. *Br J Dermatol*, 140:875–81.
- Dupont C, Vasseur E, Beauchet A, et al. 2000. Long-term efficacy on Kaposi's sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patients. *CISIH 92. Aids*, 14:987–93.
- Dvorak HF, Nagy JA, Dvorak JT, et al. 1988. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. *Am J Pathol*, 133:95–109.
- Elliott P. 2006. Pathogenesis of cardiotoxicity induced by anthracyclines. *Semin Oncol*, 33:S2–7.
- Eltom MA, Jemal A, Mbulaiteye SM, et al. 2002. Trends in Kaposi's sarcoma and non-Hodgkin's lymphoma incidence in the United States from 1973 through 1998. *J Natl Cancer Inst*, 94:1204–10.
- Embre L, Gelmon K, Tolcher A, et al. 1998. Pharmacokinetic behavior of vincristine sulfate following administration of vincristine sulfate liposome injection. *Cancer Chemother Pharmacol*, 41:347–52.
- Engels EA, Pfeiffer RM, Goedert JJ, et al. 2006. Trends in cancer risk among people with AIDS in the United States 1980–2002. *Aids*, 20:1645–54.
- Evans SR, Krown SE, Testa MA, et al. 2002. Phase II evaluation of low-dose oral etoposide for the treatment of relapsed or progressive AIDS-related Kaposi's sarcoma: an AIDS Clinical Trials Group clinical study. *J Clin Oncol*, 20:3236–41.

- Forssen EA, Coulter DM, Proffitt RT. 1992. Selective in vivo localization of daunorubicin small unilamellar vesicles in solid tumors. *Cancer Res*, 52:3255–31.
- Froelich-Ammon SJ, Osheroff N. 1995. Topoisomerase poisons: harnessing the dark side of enzyme mechanism. *J Biol Chem*, 270:21429–32.
- Fumagalli L, Zucchetti M, Parisi I, et al. 2000. The pharmacokinetics of liposomal encapsulated daunorubicin are not modified by HAART in patients with HIV-associated Kaposi's sarcoma. *Cancer Chemother Pharmacol*, 45:495–501.
- Gelmon KA, Tolcher A, Diab AR, et al. 1999. Phase I study of liposomal vincristine. *J Clin Oncol*, 17:697–705.
- Gilead Sciences, Ltd. 2000. Summary of product characteristics: DaunoXome [online]. Accessed 18 October 2006. URL: http://www.gilead.com/pdf/uk/dx_spc.pdf.
- Gill PS, Espina BM, Muggia F, et al. 1995. Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin. *J Clin Oncol*, 13:996–1003.
- Gill PS, Tulpule A, Espina BM, et al. 1999. Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi's sarcoma. *J Clin Oncol*, 17:1876–83.
- Gill PS, Wernz J, Scadden DT, et al. 1996. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. *J Clin Oncol*, 14:2353–64.
- Handa K, Sato S. 1975. Generation of free radicals of quinone group-containing anti-cancer chemicals in NADPH-microsome system as evidenced by initiation of sulfite oxidation. *Gann*, 66:43–7.
- Hjortsberg C, Persson U, Lidbrink E, et al. 1999. Cost-effectiveness analysis of pegylated-liposomal doxorubicin and liposomal daunorubicin treatments in patients with Kaposi's sarcoma. *Acta Oncol*, 38:1063–7.
- Hobbs SK, Monsky WL, Yuan F, et al. 1998. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. *Proc Natl Acad Sci USA*, 95:4607–12.
- Hofheinz RD, Gnad-Vogt SU, Beyer U, et al. 2005. Liposomal encapsulated anti-cancer drugs. *Anticancer Drugs*, 16:691–707.
- Huang SK, Lee KD, Hong K, et al. 1992. Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice. *Cancer Res*, 52:5135–43.
- Hwang K. 1987. Liposome pharmacokinetics in liposomes: from biophysics to therapeutics. New York: Marcel Dekker, Inc.
- Jain RK. 1987. Transport of molecules across tumor vasculature. *Cancer Metastasis Rev*, 6:559–593.
- Kigula-Mugambe JB, Kavuma A. 2005. Epidemic and endemic Kaposi's sarcoma: a comparison of outcomes and survival after radiotherapy. *Radiother Oncol*, 76:59–62.
- Koon HB, Bubley GJ, Pantanowitz L, et al. 2005. Imatinib-induced regression of AIDS-related Kaposi's sarcoma. *J Clin Oncol*, 23:982–9.
- Krown SE, Metroka C, Wernz JC. 1989. Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee. *J Clin Oncol*, 7:1201–7.
- Krown SE, Northfelt DW, Osoba D, et al. 2004. Use of liposomal anthracyclines in Kaposi's sarcoma. *Semin Oncol*, 31:36–52.
- Krown SE, Real FX, Cunningham-Rundles S, et al. 1983. Preliminary observations on the effect of recombinant leukocyte A interferon in homosexual men with Kaposi's sarcoma. *N Engl J Med*, 308:1071–6.
- Lane HC, Kovacs JA, Feinberg J, et al. 1988. Anti-retroviral effects of interferon-alpha in AIDS-associated Kaposi's sarcoma. *Lancet*, 2:1218–22.
- Lebbe C, Blum L, Pellet C, et al. 1998. Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma. *Aids*, 12:F45–49.
- Lefrak EA, Pitha J, Rosenheim S, et al. 1973. A clinicopathologic analysis of adriamycin cardiotoxicity. *Cancer*, 32:302–14.
- Li X, Hirsh DJ, Cabral-Lilly D, et al. 1998. Doxorubicin physical state in solution and inside liposomes loaded via a pH gradient. *Biochim Biophys Acta*, 1415:23–40.
- Lim ST, Levine AM. 2005. Recent advances in acquired immunodeficiency syndrome (AIDS)-related lymphoma. *CA Cancer J Clin*, 55:229–41; 260–1, 264.
- Little RF, Pittaluga S, Grant N, et al. 2003. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. *Blood*, 101:4653–9.
- Mayer LD, Bally MB, Cullis PR. 1986. Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient. *Biochim Biophys Acta*, 857:123–6.
- Monini P, Sgadari C, Toschi E, et al. 2004. Antitumor effects of antiretroviral therapy. *Nat Rev Cancer*, 4:861–75.
- Murdaca G, Campelli A, Setti M, et al. 2002. Complete remission of AIDS/Kaposi's sarcoma after treatment with a combination of two nucleoside reverse transcriptase inhibitors and one non-nucleoside reverse transcriptase inhibitor. *Aids*, 16:304–5.
- Nabiev IR, Morjani H, Manfait M. 1991. Selective analysis of antitumor drug interaction with living cancer cells as probed by surface-enhanced Raman spectroscopy. *Eur Biophys J*, 19:311–16.
- Netageri GV, Jenkins SA, Parsons DL. 1993. Liposome drug delivery systems. Lancaster, PA: Technomic Publishing Company, Inc.
- Paparizos VA, Kyriakis KP, Papastamopoulos V, et al. 2002. Response of AIDS-associated Kaposi sarcoma to highly active antiretroviral therapy alone. *J Acquir Immune Defic Syndr*, 30:257–8.
- Patel HM, Russell NJ. 1988. Liposomes: from membrane model to therapeutic applications. *Biochem Soc Trans*, 16:909–10.
- Presant CA, Scolaro M, Kennedy P, et al. 1993. Liposomal daunorubicin treatment of HIV-associated Kaposi's sarcoma. *Lancet*, 341:1242–3.
- Quinn TC, Overbaugh J. 2005. HIV/AIDS in women: an expanding epidemic. *Science*, 308:1582–3.
- Ratner L, Lee J, Tang S, et al. 2001. Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. *J Clin Oncol*, 19:2171–8.
- Real FX, Oettgen HF, Krown SE. 1986. Kaposi's sarcoma and the acquired immunodeficiency syndrome: treatment with high and low doses of recombinant leukocyte A interferon. *J Clin Oncol*, 4:544–51.
- Robert J. 1998. Anthracyclines. In Grochow LB, Ames MM. eds. A clinician's guide to chemotherapy pharmacokinetics and pharmacodynamics. Baltimore, MD: William and Wilkins. p. 93–174.
- Roerdink FH, Daemen T, Baker-Woudenberg IAJM, et al. 1987. In Johnson P, Llyod-Jones JG. eds. Therapeutic utility of liposomes in drug delivery systems: fundamentals and techniques. Chichester, England: Ellis Horwood, Ltd. p. 66–80.
- Rosenthal E, Poizot-Martin I, Saint-Marc T, et al. 2002. Phase IV study of liposomal daunorubicin (DaunoXome) in AIDS-related Kaposi sarcoma. *Am J Clin Oncol*, 25:57–9.
- Sessa G, Weissmann G. 1968. Phospholipid spherules (liposomes) as a model for biological membranes. *J Lipid Res*, 9:310–18.
- Sin SH, Roy D, Wang L, et al. 2007. Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling. *Blood*, 109:2165–73.
- Sinha BK. 1989. Free radicals in anticancer drug pharmacology. *Chem Biol Interact*, 69:293–317.
- Sinha BK, Politi PM. 1990. Anthracyclines. *Cancer Chemother Biol Response Modif*, 11:45–57.
- Soulhier J, Grollet L, Oksenhendler E, et al. 1995. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. *Blood*, 86:1276–80.
- Stallone G, Schena A, Infante B, et al. 2005. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. *N Engl J Med*, 352:1317–23.
- Stein ME, Lakier R, Spencer D, et al. 1994. Radiation therapy for non-AIDS associated (classic and endemic African) and epidemic Kaposi's sarcoma. *Int J Radiat Oncol Biol Phys*, 28:613–619.
- Stewart S, Jablonowski H, Goebel FD, et al. 1998. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International Pegylated Liposomal Doxorubicin Study Group. *J Clin Oncol*, 16:683–91.
- Tappero JW, Conant MA, Wolfe SF, et al. 1993. Kaposi's sarcoma. Epidemiology, pathogenesis, histology, clinical spectrum, staging criteria and therapy. *J Am Acad Dermatol*, 28:371–95.

- Tewey KM, Chen, GL, Nelson EM, et al. 1984. Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. *J Biol Chem*, 259:9182–7.
- Thurston G, McLean JW, Rizen M, et al. 1998. Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. *J Clin Invest*, 101:1401–13.
- Treat J, Damjanov N, Huang C, et al. 2001. Liposomal-encapsulated chemotherapy: preliminary results of a phase I study of a novel liposomal paclitaxel. *Oncology (Williston Park)*, 15:44–8.
- Tulpule A, Yung RC, Wernz J, et al. 1998. Phase II trial of liposomal daunorubicin in the treatment of AIDS-related pulmonary Kaposi's sarcoma. *J Clin Oncol*, 16:3369–74.
- UNAIDS. 2006. 2006 report on the global AIDS epidemic: a UNAIDS 10th anniversary special edition [online]. Accessed 16 October 2006. URL: http://www.unaids.org/en/HIV_data/2006GlobalReport/default.asp
- Von Hoff DD, Layard MW, Basa P, et al. 1979. Risk factors for doxorubicin-induced congestive heart failure. *Ann Intern Med*, 91:710–17.
- von Moltke LL, Greenblatt DJ, Grassi JM, et al. 1998. Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir. *J Clin Pharmacol*, 38:106–11.
- Welles L, Saville MW, Lietzau, J, et al. 1998. Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma. *J Clin Oncol*, 16:1112–21.
- Wilkinson J, Cope A, Gill J, et al. 2002. Identification of Kaposi's sarcoma-associated herpesvirus (KSHV)-specific cytotoxic T-lymphocyte epitopes and evaluation of reconstitution of KSHV-specific responses in human immunodeficiency virus type 1-infected patients receiving highly active antiretroviral therapy. *J Virol*, 76:2634–40.
- Young AM, Dhillon T, Bower M. 2004. Cardiotoxicity after liposomal anthracyclines. *Lancet Oncol*, 5:654.